Dresden University of Technology, Germany
Michael Gelinsky studied Chemistry at the University of Freiburg in Germany and did there also his PhD on a topic of bioinorganic chemistry. In 1999 he moved to Dresden University of Technology (TU Dresden) and started to work on biomaterials at the Institute of Materials Science. In 2002 he became head of the research group “Tissue Engineering and Biomineralisation” at the newly founded Max Bergmann Center of Biomaterials. In 2010 he was appointed full professor by the Medical Faculty of TU Dresden. Since then he heads the Centre for Translational Bone, Joint and Soft Tissue Research, a central research unit of Medical Faculty and University Hospital.
The work of Michael Gelinsky and his group is focused on biomaterials design for hard and soft tissues, tissue engineering, translational musculoskeletal medicine and 3D printing/bioprinting. He is also a founder member of the Center for Regenerative Therapies Dresden (CRTD) of TU Dresden University which is part of the German Federal Initiative of Excellence.
Goethe University, Frankfurt, Germany
Charles James Kirkpatrick has a triple doctorate in science and medicine (MD, PhD, DSc) from the Queen’s University of Belfast (N. Ireland). He is emeritus Professor of Pathology at the University Medical Center in Mainz, Germany and now Senior Professor at the Goethe University in Frankfurt. His academic appointments were at the University of Ulm, Manchester University, the RWTH Aachen (1987-1993) and the Johannes Gutenberg University (JGU) Mainz. He is a Fellow of the Royal College of Pathologists (FRCPath), London and has both honorary and visiting professorships in China, Singapore and Sweden. His principal research interests are in the fields of biomaterials in regenerative medicine, with special focus on human co-culture systems. During the past years his work has involved bone vascularization, the development of barrier models (e.g. air-blood barrier, blood-brain barrier) to study nanoparticle interactions with cellular systems, as well as co-culture models for upper respiratory tract regeneration.
He is author/coauthor of 511 publications in peer-reviewed journals, has given more than 500 invited lectures at scientific meetings worldwide and has an h-index of 56 (Web of Science) & 68 (Google Scholar) with > 17.000 citations. He has supervised 116 doctorate theses (MD, PhD, DDS) at two universities in Germany (Aachen, Mainz). He is a former President of both the German and European Society for Biomaterials. In 2008 he received the ESB’s George Winter Award, and in 2010 he was awarded the Chapman Medal from the Institute of Materials, Minerals & Mining, London, for “distinguished research in the field of biomedical materials”. In 2014 he received the TERMIS-EU Career Achievement Award (awarded at the TERMIS congress in Genova, Italy).
Laval University, Quebec, Canada
Holder of the Canada Research Chair in Biomaterials and Bioengineering for the Innovation in Surgery, professor at the Department of Materials Engineering at Laval University, adjunct director at the Division of Regenerative Medicine of the Research Center of the CHU de Québec, Diego Mantovani is a recognised specialist in biomaterials. At the frontier between engineering, medicine and biology, within his team, their works aim to improve the clinical performances of medical devices for functional replacement, and to envisage the next generations of biomaterials to develop artificial organs enhancing the quality of the life of patients.
He has authored more than 200 original articles, holds 4 patents, and presented more than 120 keynotes, invited and seminar lectures worldwide in the field of advanced materials for biomedical applications. His H-Factor is 38 (Feb2017) and his works received more than 4500 citations. In 2012, he was nominated Fellow of the International Union of Societies for Biomaterials Science & Engineering (FBSE) for his leadership and contribution to biomaterials for medical devices. He was Executive Co-Chair of the 10th World Biomaterials Congress 2016. He isadvisor of three medical devices consortium in the Americas, Asia and Europe.
Queensland University of Technology, Brisbane, Australia
Dr Mia Woodruff leads the Biofabrication and Tissue Morphology Group. She attained her PhD in 2006 and has published over 40 papers. She is an expert in bone tissue engineering with extensive experience in all aspects of biomaterial scaffold fabrication techniques and pre-clinical models and has built a world-leading histology laboratory.
Mia’s exciting vision is of a future where the fabrication of patient-specific replacement tissue and organs is safe, cost-effective and routine. This dream drives her fascinating research to advance the high-tech sciences of tissue engineering and biofabrication.
Cranfield University, UK
Peter Zioupos is a Professor of Forensic Biomechanics at Cranfield University. His research focuses on the material science of biological materials and hard and soft tissues in particular. He has spent 25 years studying the structure, pathophysiology and performance of human and animal bones. A good example of applications which accrue from such knowledge is a method with a patent he has developed for the forensic determination of age at time of death by analytical laboratory examination of bone matrix. He appeared in two recent TV documentaries: one for Discovery Channel on "free fall" accidents, and a second for National Geographic on the circumstances surrounding the unexpected "death of King Tutankhamen". Peter is also very active within the community of the European Society of Biomechanics.
He has served as a Vice-President of the European Society of Biomechanics (2012-14) and was first elected to the Council in July 2006. He served as Chair of the ‘Education Committee' (2006-08) and later as Chair of the ‘Meetings Committee' (2008-12). In 2008, Peter was awarded the Degree of Doctor of Science by the Senate of Strathclyde University following the recommendation by the Higher Doctorates Committee for his work on ‘Composite aspects of basic bone biomechanics: structure/function relationships and applications'. In 2009 Peter was elected a Fellow of the IPEM (Institute of Physics and Engineering in Medicine). Over the past 25 years he has published over 80 peer review articles in bone mechanics, which have gathered over 3700 citations. Of these, 13 papers in particular are now ‘classics' in the field of basic bone biomechanics with more than 100 citations each.
Scottish National Blood Transfusion Service
Dr Alasdair Fraser originally trained as a parasitologist in Aberdeen and Leeds, working in projects at Salford University including fieldwork in Mexico, Indonesia, Australia and Jordan. After five years of being bitten by insects, pigs, dogs and small children he decided to move to the safer territory of immunology, heading to Glasgow to work on cancer and autoimmune disease with Professors Tessa Holyoake, Ian McInnes and Gerry Graham investigating the immune response to leukaemias, rheumatoid arthritis and other inflammatory diseases.
In 2014 he moved to the Research, Development and Innovation section of the Scottish National Blood Transfusion Service, translating his understanding of the immune response into clinical therapy. His role is to develop new cell therapies up to Good Manufacturing Practice (GMP) standard and lead on the functional and phenotypic characterization of these products. He runs a group responsible for several new therapies including stem cells, Epstein-Barr Virus specific T cells for cancer treatment, endothelial cells for vascular disease and clinical grade macrophages for treatment of cirrhotic liver disease. He has published over thirty papers and holds positions at Glasgow University (Honorary Senior Lecturer) and Heriot Watt University (Honorary Associate Professor).
Regulation Manager at the Human Tissue Authority
Amy Thomas has been a Regulation Manager at the Human Tissue Authority since 2012, where her role focuses on regulatory policy development with a particular interest in tissue and cell based therapies. This includes leading on the regulatory status of emerging and borderline therapies, joint working initiatives with other regulatory bodies and implementation of new areas of European legislation.
Amy is a member of the team which reviews and authorises cell and tissue preparation processes, is involved in the monitoring of serious adverse events and reactions across all cell and tissue therapy areas and has served as the HTA’s representative on the national safety advisory committees for tissues and cells used in patient treatment.
Amy trained as a pharmacologist and has worked in pre-clinical drug development, within both the pharmaceutical industry and academia. Her PhD and postdoctoral research work focused on the clinical translation of cell based systems.